Overcoming Prostate Cancer
A survivor tells his story
Listen to Less Hunt from Gippsland FM radio interview Alan White, prostate cancer survivor. Alan shares his personal experience of being diagnosed with low risk - then later - intermediate risk prostate cancer. Alan is candid about his treatment and the side-effects including the impact on sexual function; and the challenges he has overcome. Alan's wife, Fiona, shares her experience about the impact of the diagnosis and decision making. Leanne Prosser, prostate cancer specialist nurse also offers her insight and advice.
Navigating active surveillance options
Interview with Natalie Richards, Declan Murphy and Renu Eapen
This episode of the GU - Cast focuses on the Navigate study and Active Surveillance as a treatment option for men with low risk prostate cancer and some men with favourable intermediate risk prostate cancer. Professor Declan Murphy and Dr Renu Eapen address some of the barriers of treatment options with Natalie Richards the Project Manager and Research Nurse for the Navigate study, such as the overwhelming nature of choosing treatment options and how the Navigate study aims to address this.
The Penis Project - Episode 11
Professor Declan Murphy appears on episode 13 of the Penis Project to discuss prostate cancer and the experiences of patients diagnosed with prostate cancer. Declan speaks about the Navigate study and the treatment options for low risk prostate cancer patients, including Active Surveillance.
Other Relevant Podcasts
ABC - This Weekend Life
Men urged to harden up on their prostate health
Prostate cancer diagnoses plummeted during the coronavirus pandemic because men were not getting checked, according to Professor Declan Murphy Consultant Urologist and Director of Genito-Urinary (GU) Oncology at Peter MacCallum Cancer Centre.
Professor Murphy said men over 50 should speak to their GP about getting their PSA level checked regularly because the difference between early detection and late detection can be life altering.
Prostate cancer is the second most common cancer in men worldwide.